ArticleApplied biochemistry and biotechnology2026
Recombinant Fusion Protein Composed of Hirudin and Annexin A5 Shows Anti-Coagulant Activity In Vitro.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to develop novel anti-coagulant protein based on phospholipid binding protein and thrombin inhibitor. Methods: Recombinant protein composed of hirudin and annexin A5 (r-HirA5) was obtained by genetic engineering and SEC-HPLC profile was used to determine the aggregation morphology. The retention of antigenic determinants was identified by Western blot analysis. The binding specificity analysis of different kinds of phospholipid molecules, phospholipid binding dose analysis, and the effect assay of Ca2+ concentration were performed to identify the characteristics of phospholipid affinity. The plasma coagulation time detection, blood clotting assay, and anti-thrombin activity determination were performed. Results: r-HirA5 was structurally stable and existed in solution as a monomer, preserving the distribution of antigenic determinants of the annexin. r-HirA5 retained most phospholipid binding properties and showed limited in vitro thrombin binding activity. r-HirA5 demonstrated good anti-coagulant effects such as delayed plasma coagulation time and prolonged APTT value. Conclusion: The recombinant protein r-HirA5 exhibits stable physiochemical characteristics and good anti-coagulant activity. This study provides the clue for the development of novel targeted anti-coagulants for thrombotic disease.
Indexed as
Identifiers
41817943What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.